Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2017

01-04-2017 | Editorial

Continuous subcutaneous insulin infusion—an opportunity for better care but not a “magic pill”

Authors: Avivit Cahn, Eytan Roitman, Genya Aharon-Hananel, Itamar Raz

Published in: Endocrine | Issue 1/2017

Login to get access

Excerpt

The recent century has witnessed significant advances in the development of insulin therapy evolving from its early discovery to the production of human insulin and the formulation of novel short and long acting analogs [1]. Insulin delivery routes have also been extensively researched, yet the subcutaneous (SC) route remains the leading and most reliable delivery mode. SC insulin may be administered by single (if appropriate) or multiple daily injections (MDIs) or by continuous SC infusion of insulin (CSII). Both treatment modalities have been significantly developed in recent decades [1, 2]. …
Literature
1.
A. Cahn, R. Miccoli, A. Dardano, S. Del Prato, New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol 3(8), 638–652 (2015)CrossRefPubMed
2.
P. Schaepelynck, P. Darmon, L. Molines, M.F. Jannot-Lamotte, C. Treglia, D. Raccah, Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps. Diabetes Metab. 37 Suppl 4, S85–S93 (2011)CrossRefPubMed
3.
E. Standl, D. Owen, New long-acting basal insulins: does benefit outweigh cost? Diabetes Care 39(Supp2), S172–S179 (2016)CrossRefPubMed
4.
D. Russell-Jones, B.W. Bode, C. De Block, E. Franek, S. Heller, C. Mathieu, A. Philis-Tsimikas, L. Rose, V. Woo, A.B. Østerskov, T. Graungaard, R.M. Bergenstal, Double-blind mealtime faster-acting insulin aspart improves glycaemic control with superior reduction in postprandial glucose excursions vs insulin aspart in type 1 diabetes: onset® 1. Diabetologia 59(Suppl 1), S6 (2016)
5.
G. Andersen, G. Meiffren, B. Alluis, A. Ranson, R. Soula, M. Gaudie, O. Soula, C. Kazda, T. Heise, S. Bruce, Ultra-rapid BioChaperone Lispro ameliorates postprandial blood glucose control compared to insulin lispro commercial formulation in subjects with type 1 diabetes mellitus. Diabetologia 59(Suppl 1), S5 (2016)
6.
E.S. Kim, G.L. Plosker, AFREZZA® (insulin human) Inhalation powder: a review in diabetes mellitus. Drugs 75(14), 1679–1686 (2015)CrossRefPubMed
7.
E. Kochba, Y. Levin, I. Raz, A. Cahn, Improved insulin pharmacokinetics using a novel microneedle device for intradermal delivery in patients with type 2 diabetes. Diabetes Technol. Ther. 18(9), 525–531 (2016)CrossRefPubMedPubMedCentral
8.
P. Pozzilli, P. Raskin, C.G. Parkin, Review of clinical trials: update on oral insulin spray formulation. Diabetes Obes. Metab. 12(2), 91–96 (2010)CrossRefPubMed
9.
J.C. Pickup, Insulin-pump therapy for type 1 diabetes mellitus. N. Engl. J. Med. 366(17), 1616–1624 (2012)CrossRefPubMed
10.
A.L. Peters, A.J. Ahmann, T. Battelino, A. Evert, I.B. Hirsch, M.H. Murad, W.E. Winter, H. Wolpert, Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2, jc20162534 (2016)
11.
K. Benkhadra, F. Alahdab, S.U. Tamhane, R.G. McCoy, L.J. Prokop, M.H. Murad, Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine (2016) doi:10.​1007/​s12020-016-1039-x, [Epub ahead of print]
12.
M.M. Fatourechi, Y.C. Kudva, M.H. Murad, M.B. Elamin, C.C. Tabini, V.M. Montori, Clinical review: hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J. Clin. Endocrinol. Metab. 94(3), 729–740 (2009)CrossRefPubMed
13.
K. Dżygało, D. Golicki, A. Kowalsk, A. Szypowska, The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials. Acta. Diabetol. 52(2), 231–238 (2015)CrossRefPubMed
14.
S.A. Little, L. Leelarathna, E. Walkinshaw, H.K. Tan, O. Chapple, A. Lubina-Solomon, T.J. Chadwick, S. Barendse, D.D. Stocken, C. Brennand, S.M. Marshall, R. Wood, J. Speight, D. Kerr, D. Flanagan, S.R. Heller, M.L. Evans, J.A. Shaw, Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS). Diabetes Care 37(8), 2114–2122 (2014)CrossRefPubMed
15.
Z. Landau, I. Raz, J. Wainstein, Y. Bar-Dayan, A. Cahn: The role of insulin pump therapy in type 2 diabetes mellitus. Diabetes Metab. Res. Rev. (2016). doi:10.​1002/​dmrr.​2822
16.
M.I. Maiorino, G. Bellastella, M. Petrizzo, M.R. Improta, C. Brancario, F. Castaldo, L. Olita, D. Giugliano, Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine 46(2), 256–262 (2014)CrossRefPubMed
17.
M.I. Maiorino, O. Casciano, E. Della Volpe, G. Bellastella, D. Giugliano, K. Esposito, Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. Endocrine 52(2), 244–252 (2016)CrossRefPubMed
18.
I. Conget, J. Castaneda, G. Petrovski, B. Guerci, A.S. Racault, Y. Reznik, O. Cohen, S. Runzis, S. de Portu, R. Aronson; OpT2mise Study Group., The impact of insulin pump therapy on glycemic profiles in patients with type 2 diabetes: Data from the OpT2mise Study. Diabetes Technol. Ther. 18(1), 22–28 (2016)CrossRefPubMedPubMedCentral
19.
G. Lepore, A. Corsi, A.R. Dodesini, I. Nosari, R. Trevisan, Continuous subcutaneous insulin infusion is better than multiple daily insulin injections in reducing glucose variability only in type 1 diabetes with good metabolic control. Diabetes Care 33(6), e81 (2010)CrossRefPubMed
20.
H.K. Tan, S.A. Little, L. Leelarathna, E. Walkinshaw, A. Lubina-Solomon, J. Hosking, J. Speight, D. Kerr, S.R. Heller, M.L. Evans, J.A. Shaw, D. Flanagan, Low-blood glucose avoidance training improves glycemic variability in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: HypoCOMPaSS Trial. Diabetes Care 39(4), e56–e58 (2016)CrossRefPubMed
21.
R.M. Bergenstal, S. Garg, S.A. Weinzimer, B.A. Buckingham, B.W. Bode, W.V. Tamborlane, F.R. Kaufman: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA (2016). doi:10.​1001/​jama.​2016.​11708
22.
P.G. Jacobs, J. El Youssef, R. Reddy, N. Resalat, D. Branigan, J. Condon, N. Preiser, K. Ramsey, M. Jones, C. Edwards, K. Kuehl, J. Leitschuh, U. Rajhbeharrysingh, J.R. Castle: Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes. Metab. (2016). doi:10.​1111/​dom.​12707
23.
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart with an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects with Type 1 Diabetes. Available at www.​clinicaltrials.​gov; trial identifier NCT0199932
Metadata
Title
Continuous subcutaneous insulin infusion—an opportunity for better care but not a “magic pill”
Authors
Avivit Cahn
Eytan Roitman
Genya Aharon-Hananel
Itamar Raz
Publication date
01-04-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1217-x

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue

Meta-Analysis

Mortality in adults with hypopituitarism: a systematic review and meta-analysis

Original Article

How do etiological factors can explain the different clinical features of patients with differentiated thyroid cancer and their histopathological findings?

Original Article

First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma

Research Letter

Migration flows affect women’s dietary iodine intake and jeopardize their iodine sufficiency: a pilot study

Original Article

Hair cortisol in the evaluation of Cushing syndrome

Original Article

Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits